Jacobio Pharmaceuticals Group Co., Ltd. repurchased 78,900 ordinary shares on 12 May 2026 through on-market transactions on the Hong Kong Stock Exchange, paying between HK$5.90 and HK$5.92 per share for a total consideration of HK$0.47 million (volume-weighted average price: HK$5.91).

Following the transaction, issued shares outstanding (excluding treasury shares) decreased by 0.010 % to 784.77 million, while treasury shares increased to 6.98 million. Total issued share capital remained unchanged at 791.76 million shares.

The buyback was conducted under the repurchase mandate granted on 10 June 2025, which authorises the company to repurchase up to 78.87 million shares. Cumulative repurchases under this mandate now stand at 3.96 million shares, equivalent to 0.50 % of the share count on the mandate date. In line with Hong Kong listing rules, Jacobio is subject to a moratorium on new share issues or treasury-share disposals until 11 June 2026.

All repurchased shares are being held as treasury shares; none have been cancelled. The company confirmed that the buyback complied with the Main Board Listing Rules and the terms of its previously filed explanatory statement.